Clinical Trials Logo

Renal Transplantation clinical trials

View clinical trials related to Renal Transplantation.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05833750 Completed - Fatigue Clinical Trials

Effects of Reflexology in Transplant Patients

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

Abstract Objective: The aim of this study is to examine the effect of reflexology on fatigue in kidney transplant patients. Design: The study will be conducted as randomized, controlled and experimental. Method: The data of the research will be collected in the transplant clinic of a foundation university practice and research hospital between 07.12.2020 - 18.06.2021. While the population of the study consisted of 254 patients who underwent kidney transplantation in the transplant unit, 68 patients were included in the sample. The patients included in the study were divided into reflexology (n=34) and control (n=34) groups with the help of a program. Data will be collected using Questionnaire and Piper Fatigue Scale. Chi-square test, Student's t test, Mann Whitney U test and Kruskal-Wallis test, correlation, generalized estimation equation and Least Significant Difference tests will be used in the evaluation of the data. Keywords: kidney transplantation, reflexology, fatigue, nursing.

NCT ID: NCT05240274 Completed - Clinical trials for End Stage Renal Disease

The POWERED Study: Prophylaxis With Metformin to Prevent PTDM

POWERED
Start date: January 25, 2019
Phase: Phase 2
Study type: Interventional

PrOphylaxis With mEtformin to pREvent PTDM: a single site, placebo controlled, double blind randomised clinical trial evaluating the effectiveness of metformin to prevent post-transplant diabetes in a cohort of patients undergoing renal transplantation.

NCT ID: NCT05208788 Completed - Clinical trials for Renal Transplantation

Urinary Biomarkers in Paediatric Kidney Transplantation (pKTx)

Start date: June 1, 2021
Phase:
Study type: Observational

This study aims to test and validate the panel of study urinary biomarker to assess whether (1) reference values differ between paediatric renal transplant patients, patients with chronic kidney disease stage IV and V (CKD IV-V) and children without any disease, (2) characteristic changes in concentration profile may be observed after event-specific injury, (3) differences between paediatric renal transplant patients with AR and other causes of AKI can be detected, and (4) stratification of renal transplant patients to different histological types of AR is possible.

NCT ID: NCT04863716 Completed - Clinical trials for Renal Transplantation

Erector Spinae Plane Block in Renal Transplantation Donors

Start date: April 28, 2021
Phase: N/A
Study type: Interventional

Erector Spina Plan Block (ESPB) is a relatively new, easy-to-apply and safe regional anesthesia technique used to provide postoperative analgesia in various surgeries. Studies showing the clinical benefits of Erector Spina Plan block in renal transplantation surgery are limited to case reports. In this study, the effect of Erector Spina Plan Block on opioid consumption in postoperative period on donor patients who will undergo laparoscopic nephrectomy in renal transplantation surgery will be examined prospectively. The aim of the study is to provide analgesia to donor patients using less opioids by Erector Spina Plan Block and provide enhanced recovery.

NCT ID: NCT04774575 Completed - Clinical trials for Renal Transplantation

Quantify the Benefits of Biomarkers in Routine Patient Care in Kidney Transplant Recipients

EUTRAIN IMPACT
Start date: December 15, 2021
Phase: N/A
Study type: Interventional

The investigator hypothesize that the combined use of (1) non-invasive biomarkers in peripheral blood predicting anti-donor immunological activation or quiescence (2) interactive and actionable data analytics delivered at the bedside will promote safe clinical follow-up of kidney transplant patients with less need for invasive and induced risk surveillance by allograft protocol biopsies to assess allograft rejection in clinically stable kidney transplant patients. It is therefore proposed an European, multicenter, prospective randomized comparing two strategies of follow-up: in the first, biopsies are guided by biomarkers, in the second one, a routine biopsy is performed at M3. In both groups, a biopsy is performed at M12 and whenever considered necessary by the clinician.

NCT ID: NCT04730492 Completed - Clinical trials for Renal Transplantation

HErnias REparation After Kidney Transplantation Study

HEREKT
Start date: November 30, 2020
Phase:
Study type: Observational

Correlation between hernias reparation in patients who have received a kidney transplant. The investigators will analyze the data of patients who have been treated for reparation of incisional hernia after kidney transplantation with or without the placement of a prosthesis.

NCT ID: NCT03830255 Completed - Clinical trials for Renal Transplantation

Effect of Genetic Polymorphism on Calcineurin Inhibitors Levels in Egyptian Renal Transplant Patients

Start date: March 1, 2017
Phase:
Study type: Observational

Renal transplantation is the treatment of choice for patients with end-stage renal disease (ESRD). Calcineurin Inhibitors tacrolimus and cyclosporine are the principle immunosuppressive agents administered to solid organ transplant recipients to prevent and treat allograft rejection. The aim of the present study is to detect the incidence of some selected genetic polymorphism in Egyptian renal transplant population and investigate the influence of these genetic polymorphism (SNPs )on Cyclosporine and Tacrolimus blood concentration. In addition to detect the association between these genetic polymorphism variants and patients' clinical outcome after transplantation.

NCT ID: NCT03098238 Completed - Clinical trials for Renal Transplantation

Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody-mediated Rejection in Kidney Transplantation

MICROMARK RJ
Start date: November 30, 2017
Phase: N/A
Study type: Interventional

Context and rationale: Antibody-mediated rejection is the leading cause of long-term renal graft loss. It's due to the production by the recipient of antibodies directed against antigens (belonging or not to the HLA system) present on the surface of the donor specific endothelial cells (DSA), leading to graft failure. The main difficulty to manage the humoral rejection is the delay of the diagnosis and the treatment to slow the evolution towards fibrosis. Positivity of anti-HLA antibodies is the main risk factor for the rejection but the only way to make the diagnosis of humoral rejection is to perform a graft biopsy, an invasive process. Endothelial microparticles (MPE) are small membrane vesicles generated by endothelial cell activation and / or apoptosis processes. We test the hypothesis that endothelial microparticles are an early diagnostic biomarker of humoral rejection in renal transplantation allowing to detect it at the "subclinical" stage. Primary and secondary objectives: The main objective of this study is to estimate the performance of MPE plasma concentration for the diagnosis of humoral rejection in renal transplant patients with DSA. The secondary objective is to investigate by mass spectrometry the MPEs specific to the endothelium of the graft and to evaluate their diagnostic performance in relation to non-specific MEPs Methodology : We will conduct a cross-sectional evaluation of a diagnostic method from a collection of biological samples. The gold standard for the diagnosis of humoral rejection is the histological diagnosis on graft biopsy. The new test under study will be the flow cytometric assay of the MPE concentration carried out on plasma taken on the day of the graft biopsy. Feasibility: Among the active list of renal transplant patients attending the Montpellier University Hospital, we estimate that we can include the number of subjects required (N = 250) over 18 months. This work will be carried out in a laboratory with all the tools and techniques used, in particular flow cytometry and mass spectrometry, perfectly mastered and realized on dedicated technical platforms Benefits / Outlook: find a non-invasive early diagnostic biomarker to detect humoral rejection from the "subclinical" stage in order to set up an adapted treatment as quickly as possible.

NCT ID: NCT03024229 Completed - Clinical trials for Renal Transplantation

Metabolomics in Assessing the Quality of Kidney Transplants Retained on a LifePort® Perfusion Machine

RENALIFE
Start date: March 15, 2017
Phase: N/A
Study type: Interventional

When the kidneys are perfused on perfusion machines before transplantation, the resistance parameters as well as the histological score on the pre-implantation biopsy participate in the evaluation of the quality of the graft. The metabolomic profile of the infusion fluid could provide additional evidence.

NCT ID: NCT02843295 Completed - Clinical trials for Renal Transplantation

Catalytic Antibodies to Predict Uninvasively Late Transplant Failure

CATAPULT
Start date: September 2010
Phase: N/A
Study type: Interventional

Chronic Allograft Nephropathy (CAN), a major cause of late allograft failure, is characterized by a progressive decline in graft function correlating with tissue destruction. Recent data suggest that it may be possible to delay graft destruction if adequate management is initiated early (ie, at the stage of subclinical CAN). It is therefore essential to design new tests allowing physicians to predict transplant recipients prone to develop CAN